Conditions:  Metastatic Lung Non-Small Cell Carcinoma;  Recurrent Lung Non-Small Cell Carcinoma;  Stage IIIC Lung Cancer AJCC v8;  Stage IV Lung Cancer AJCC v8;  Stage IVA Lung Cancer AJCC v8;  Stage IVB Lung Cancer AJCC v8
Interventions: Â Biological:Â Bevacizumab; Â Drug:Â Carboplatin; Â Drug:Â Ensartinib; Â Drug:Â Pemetrexed
Sponsor:  M.D. Anderson Cancer Center
**RECRUITING NOW**
Interventions: Â Biological:Â Bevacizumab; Â Drug:Â Carboplatin; Â Drug:Â Ensartinib; Â Drug:Â Pemetrexed
Sponsor:  M.D. Anderson Cancer Center
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
